Pelthos Therapeutics Inc.
PTHS
$23.42
-$1.13-4.60%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 43.30M | 27.70M | 16.80M | 7.41M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.30M | 27.70M | 16.80M | 7.41M | -- |
| Cost of Revenue | 10.58M | 6.88M | 5.22M | 3.46M | 1.41M |
| Gross Profit | 32.73M | 20.82M | 11.58M | 3.95M | -1.41M |
| SG&A Expenses | 85.37M | 61.92M | 42.45M | 25.52M | 7.53M |
| Depreciation & Amortization | 3.63M | 2.59M | 1.56M | 679.00K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 99.58M | 71.39M | 49.23M | 29.66M | 8.94M |
| Operating Income | -56.28M | -43.68M | -32.43M | -22.25M | -8.94M |
| Income Before Tax | -93.78M | -73.81M | -50.71M | -24.05M | -9.04M |
| Income Tax Expenses | -7.39M | -7.39M | -7.39M | -465.00K | -- |
| Earnings from Continuing Operations | -86.39 | -66.42 | -43.32 | -23.58 | -9.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.39M | -66.42M | -43.32M | -23.58M | -9.04M |
| EBIT | -56.28M | -43.68M | -32.43M | -22.25M | -8.94M |
| EBITDA | -51.88M | -37.38M | -25.79M | -15.01M | -- |
| EPS Basic | -26.36 | -25.03 | -20.67 | -17.00 | -14.62 |
| Normalized Basic EPS | -17.62 | -17.05 | -14.33 | -10.72 | -9.14 |
| EPS Diluted | -26.36 | -25.03 | -20.67 | -17.00 | -14.62 |
| Normalized Diluted EPS | -17.62 | -17.05 | -14.33 | -10.72 | -9.14 |
| Average Basic Shares Outstanding | 13.07M | 10.18M | 7.48M | 4.93M | 2.45M |
| Average Diluted Shares Outstanding | 13.07M | 10.18M | 7.48M | 4.93M | 2.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |